Gilead Sciences Reaches $158.69, Its Second 52-Week High in Two Weeks
As seen on the 24/7 Wall St. homepage on October 26, 2026.
Gilead Sciences set a new 52-week high at $158.69, clearing its October 15 peak by 0.84% and making this the second record in under two weeks. The $196.8 billion biotech is now roughly a third above where it traded a year ago.
Continue ReadingShow less
Gilead Sciences touched $158.69 on October 26, topping the prior 52-week peak set just on October 15. Back-to-back record highs within a two-week window signal sustained buying pressure.
That roughly one-third gain over twelve months is meaningful for a company of this scale. Gilead carries a market capitalization of $196.8 billion, so the move higher reflects a substantial shift in how the market is pricing the business.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The pace of the recent leg is worth noting. The stock spent much of the spring and early summer consolidating in the $123 to $135 range before accelerating to new highs. A base plus breakout often draws institutional attention.
Investors keeping an eye on the stock will want to see whether it can hold above the October 15 level on any near-term pullback. A failure to do so would mark the latest high as a short-term overshoot.
Sources
Mentioned: GILD